公开(公告)号：EP3280795A1

公开(公告)日：2018-02-14

申请号：EP16718786.3

申请日：2016-04-07

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania ,  Byrd, John ,  Dubovsky, Jason ,  Johnson, Amy ,  June, Carl, H. ,  Muthusamy, Natarajan ,  Porter, David L. ,  Wasik, Mariusz

发明人： BYRD, John ,  DUBOVSKY, Jason ,  JOHNSON, Amy ,  JUNE, Carl, H. ,  MUTHUSAMY, Natarajan ,  PORTER, David, L. ,  WASIK, Mariusz ,  ANGST, Daniela ,  FRAIETTA, Joseph, A. ,  GESSIER, Francois ,  GILL, Saar ,  MAUS, Marcela ,  RUELLA, Marco ,  VULPETTI, Anna

IPC分类号： C12N5/0783 ,  A61K31/505 ,  A61K31/506 ,  A61K45/06

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K35/17 ,  A61K45/06 ,  A61K2035/124 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/00 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0636 ,  A61K2300/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.

公开(公告)号：EP4406610A2

公开(公告)日：2024-07-31

申请号：EP24166976.1

申请日：2015-04-07

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： BYRD, John ,  DUBOVSKY, Jason ,  FRAIETTA, Joseph ,  GILL, Saar ,  GLASS, David ,  JOHNSON, Amy ,  JUNE, Carl H. ,  KENDERIAN, Saad ,  MANNICK, Joan ,  MAUS, Marcela ,  MURPHY, Leon ,  MUTHUSAMY, Natarajan ,  PORTER, David L. ,  RUELLA, Marco ,  SELLERS, William Raj ,  WASIK, Mariusz ,  BROGDON, Jennifer

IPC分类号： A61P35/02

CPC分类号： C12N5/0636 ,  C12N2501/72720130101 ,  C07K16/2803 ,  A61K31/519 ,  A61K45/06 ,  A61K31/436 ,  A61K31/53 ,  C07K2317/62220130101 ,  C07K2319/0320130101 ,  C07K2317/7320130101 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00 ,  A61K39/001112 ,  A61K2239/3820230501 ,  A61K39/4631 ,  A61K2239/2620230501 ,  A61K2239/4820230501 ,  A61K39/464412 ,  A61K2239/3120230501 ,  A61K39/4611 ,  A61K39/4636

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

公开(公告)号：EP3888674A1

公开(公告)日：2021-10-06

申请号：EP21160203.2

申请日：2015-04-07

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： BYRD, John ,  DUBOVSKY, Jason ,  FRAIETTA, Joseph ,  GILL, Saar ,  GLASS, David ,  JOHNSON, Amy ,  JUNE, Carl H. ,  KENDERIAN, Saad ,  MANNICK, Joan ,  MAUS, Marcela ,  MURPHY, Leon ,  MUTHUSAMY, Natarajan ,  PORTER, David L. ,  RUELLA, Marco ,  SELLERS, William Raj ,  WASIK, Mariusz ,  BROGDON, Jennifer

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61K31/436 ,  A61P35/02

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

公开(公告)号：EP4056588A1

公开(公告)日：2022-09-14

申请号：EP22162298.8

申请日：2016-04-08

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： BITTER, Hans ,  BORDEAUX, Jennifer Mary ,  BRANNETTI, Barbara ,  BROGDON, Jennifer ,  DAKAPPAGARI, Naveen Kumar ,  GILL, Saar ,  HIGHFILL, Steven ,  HUANG, Lu ,  JUNE, Carl H. ,  KIM, Ju Young ,  LEI, Ming ,  LI, Na ,  LOEW, Andreas ,  ORLANDO, Elena ,  RUELLA, Marco ,  TRAN, Thai ,  ZHANG, Jimin ,  ZHOU, Li

IPC分类号： C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

公开(公告)号：EP3280729A2

公开(公告)日：2018-02-14

申请号：EP16719611.2

申请日：2016-04-08

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： BITTER, Hans ,  BORDEAUX, Jennifer, Mary ,  BRANNETTI, Barbara ,  BROGDON, Jennifer ,  DAKAPPAGARI, Naveen, Kumar ,  GILL, Saar ,  HIGHFILL, Steven ,  HUANG, Lu ,  JUNE, Carl, H. ,  KIM, Ju, Young ,  LEI, Ming ,  LI, Na ,  LOEW, Andreas ,  ORLANDO, Elena ,  RUELLA, Marco ,  TRAN, Thai ,  ZHANG, Jimin ,  ZHOU, Li

IPC分类号： C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

CPC分类号： C07K14/70596 ,  A61K38/00 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/70 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2319/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

公开(公告)号：EP3172234A1

公开(公告)日：2017-05-31

申请号：EP15745069.3

申请日：2015-07-21

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： KENDERIAN, Saad ,  BROGDON, Jennifer ,  EBERSBACH, Hilmar ,  GILL, Saar ,  GLASS, David ,  HUBER, Thomas ,  JASCUR, Julia ,  MANNICK, Joan ,  MILONE, Michael C. ,  MURPHY, Leon ,  RICHARDSON, Celeste ,  SINGH, Reshma ,  SONG, Huijuan ,  WU, Qilong ,  ZHANG, Jiquan

IPC分类号： C07K16/28 ,  C07K16/30 ,  C07K14/725 ,  C07K14/705 ,  A61K39/395 ,  A61K31/436 ,  A61K35/17 ,  A61P35/02

CPC分类号： C07K16/2851 ,  A61K31/436 ,  A61K31/711 ,  A61K35/28 ,  A61K38/00 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/39558 ,  A61K45/06 ,  A61K48/00 ,  A61K2039/505 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7056 ,  C07K14/70578 ,  C07K14/7151 ,  C07K16/2803 ,  C07K16/30 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70 ,  A61K2300/00

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

摘要翻译： 本发明提供用于治疗与CD33表达相关的疾病的组合物和方法。 本发明还涉及对CD33特异性的嵌合抗原受体（CAR），编码它的载体和包含CD33 CAR的重组T细胞。 本发明还包括施用基因修饰的表达包含CD33结合结构域的CAR的T细胞的方法。

公开(公告)号：EP4406610A3

公开(公告)日：2024-10-30

申请号：EP24166976.1

申请日：2015-04-07

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： BYRD, John ,  DUBOVSKY, Jason ,  FRAIETTA, Joseph ,  GILL, Saar ,  GLASS, David ,  JOHNSON, Amy ,  JUNE, Carl H. ,  KENDERIAN, Saad ,  MANNICK, Joan ,  MAUS, Marcela ,  MURPHY, Leon ,  MUTHUSAMY, Natarajan ,  PORTER, David L. ,  RUELLA, Marco ,  SELLERS, William Raj ,  WASIK, Mariusz ,  BROGDON, Jennifer

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61K31/436 ,  A61P35/02

摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

公开(公告)号：EP3171882A1

公开(公告)日：2017-05-31

申请号：EP15744448.0

申请日：2015-07-21

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： KENDERIAN, Saad ,  BROGDON, Jennifer ,  EBERSBACH, Hilmar ,  GILL, Saar ,  GLASS, David ,  JASCUR, Julia ,  MANNICK, Joan ,  MILONE, Michael, C. ,  MURPHY, Leon ,  RICHARDSON, Celeste ,  SINGH, Reshma ,  WEI, Lai ,  WU, Qilong ,  YANG, Qiumei ,  ZHANG, Jiquan

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K16/28

CPC分类号： A61K39/0011 ,  A61K31/7068 ,  A61K35/17 ,  A61K45/06 ,  A61K2039/5156 ,  C07K14/7051 ,  C07K14/70578 ,  C07K16/2851 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

摘要： The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

摘要翻译： 本发明提供了用于治疗与CLL-1表达相关的疾病的组合物和方法。 本发明还涉及对CLL-1特异性的嵌合抗原受体（CAR），编码它的载体和包含CLL-1 CAR的重组细胞。 本发明还包括施用表达包含CLL-1结合结构域的CAR的基因修饰细胞的方法。

公开(公告)号：EP2958942A1

公开(公告)日：2015-12-30

申请号：EP14711341.9

申请日：2014-02-20

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： BROGDON, Jennifer ,  GILL, Saar ,  JUNE, Carl, H. ,  KALOS, Michael, D. ,  LOEW, Andreas ,  SCHOLLER, John

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00

摘要： The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.

摘要翻译： 本发明提供了组合物和方法用于治疗白血病的，例如，急性髓性白血病（AML）和B细胞急性淋巴性白血病（B-ALL）。 因此，本发明涉及特异于CD123至少一种嵌合抗原受体（CAR），载体包含相同和重组的T细胞，其包括的CD123 CAR。 因此，本发明包括施用表达CAR做了遗传修饰的T细胞包括CD123结合结构域的方法。 因此，本发明包括骨髓消融治疗中迫使骨髓或修复移植的使用方法。

公开(公告)号：EP2958942B1

公开(公告)日：2020-06-03

申请号：EP14711341.9

申请日：2014-02-20

申请人： Novartis AG ,  The Trustees of The University of Pennsylvania

发明人： BROGDON, Jennifer ,  GILL, Saar ,  JUNE, Carl, H. ,  KALOS, Michael, D. ,  LOEW, Andreas ,  SCHOLLER, John

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00 ,  A61K38/17